An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosis

被引：0
|
作者：
Galazka, A. [1 ]
Nolting, A. [2 ]
Cook, S. [3 ]
Leist, T. [4 ]
Comi, G. [5 ]
Montalban, X. [6 ,7 ]
Hicking, C. [2 ]
Dangond, F. [8 ]
机构：
[1] Merck, Aubonne, Switzerland
[2] Merck KGaA, Darmstadt, Germany
[3] Rutgers State Univ, New Jersey Med Sch, Newark, NJ USA
[4] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[5] Univ Vita Salute San Raffaele, Milan, Italy
[6] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada
[7] Hosp Univ Vall dHebron, Ctr Esclerosi Multiple Catalunya Cemcat, Barcelona, Spain
[8] EMD Serono Inc, Billerica, MA USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2018年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO1083
引用
收藏
页码：133 / 133
页数：1
相关论文
共 50 条
  • [31] Cladribine tablets in the treatment of patients with multiple sclerosis (MS): an integrated analysis of safety from the MS clinical development program
    Cook, Stuart
    Leist, Thomas
    Comi, Giancarlo
    Montalban, Xavier
    Sylvester, Elke
    Hicking, Christine
    Dangond, Fernando
    NEUROLOGY, 2017, 88
  • [32] Expert opinion consensus on recommendations for treating relapsing multiple sclerosis with cladribine tablets in daily clinical practice
    Sorensen, P. Soelberg
    Centonze, D.
    Giovannoni, G.
    Montalban, X.
    Selchen, D.
    Vermersch, P.
    Wiendl, H.
    Yamout, B.
    Salloukh, H.
    Rieckmann, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 945 - 946
  • [33] Real-World Outcomes With Cladribine Tablets in People With Relapsing Multiple Sclerosis
    Okuda, Darin
    Livingston, Terrie
    Moog, Tatum
    Smith, Alexander
    Lebson, Lori
    Piette, Elizabeth
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1100 - 1100
  • [34] Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
    Clavelou, Pierre
    Castelnovo, Giovanni
    Pourcher, Valerie
    De Seze, Jerome
    Vermersch, Patrick
    Ben-Amor, Ali-Frederic
    Savarin, Carine
    Defer, Gilles
    NEUROLOGY AND THERAPY, 2023, 12 (05) : 1457 - 1476
  • [35] Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review
    Giovannoni, Gavin
    Mathews, Joela
    NEUROLOGY AND THERAPY, 2022, 11 (02) : 571 - 595
  • [36] Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
    Pierre Clavelou
    Giovanni Castelnovo
    Valérie Pourcher
    Jerome De Sèze
    Patrick Vermersch
    Ali-Frederic Ben-Amor
    Carine Savarin
    Gilles Defer
    Neurology and Therapy, 2023, 12 : 1457 - 1476
  • [37] Danish experience with cladribine tablets in the treatment of relapsing multiple sclerosis: a nationwide study
    Sorensen, P. S.
    Heick, A.
    Petersen, T.
    Joensen, H.
    Kopp, T. I.
    Sellebjerg, F.
    Magyari, M.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 165 - 165
  • [38] CLARITY: an analysis of severity and frequency of relapses in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets or placebo
    Schippling, S.
    Sormani, M. P.
    De Stefano, N.
    Giovannoni, G.
    Galazka, A.
    Keller, B.
    Alexandri, N.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 258 - 259
  • [39] Analysis of Influenza and Varicella Zoster Virus Vaccine Antibody Titers in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets
    Roy, S.
    Boschert, U.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 43 - 44
  • [40] CLARITY: An Analysis of Severity and Frequency of Relapses in Patients with Relapsing-remitting Multiple Sclerosis Treated with Cladribine Tablets or Placebo
    Schippling, S.
    Sormani, M. P.
    De Stefano, N.
    Giovannoni, G.
    King, J.
    Galazka, A.
    Keller, B.
    Alexandri, N.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (03) : 466 - 467
12345